The UK Government has formally accepted all 44 recommendations made by the National Commission into the Regulation of AI in Healthcare, marking a significant shift in how artificial intelligence-enabled medical devices will be regulated across the UK.
The announcement, made today, outlines plans to move away from a reliance on one-off regulatory approvals towards a more agile, lifecycle-based approach that continuously monitors AI technologies throughout their use in healthcare settings.
Alongside the government response, the Medicines and Healthcare products Regulatory Agency (MHRA) has opened applications for AI Airlock Phase 3, the next stage of its regulatory sandbox programme designed to test innovative approaches to AI-enabled medical device regulation.
The National Commission concluded that the UK’s existing regulatory framework must evolve to keep pace with rapidly developing AI technologies. Central to its findings was the recommendation that AI-enabled medical devices should be assessed and monitored throughout their operational life, rather than relying heavily on a single pre-market assessment.
In response, the Government has committed to developing what it describes as a world-leading regulatory model that balances innovation with patient safety, transparency and public trust.
The reforms are intended to accelerate access to safe and effective AI-powered healthcare technologies while ensuring robust oversight as these systems continue to learn, adapt and improve.
The launch of AI Airlock Phase 3 represents one of the first practical steps in delivering the Commission’s recommendations.
The programme will focus on post-market surveillance and lifecycle regulation, bringing together developers, regulators and NHS partners to explore how AI-enabled medical devices can be monitored safely after deployment in real-world clinical environments.
Insights gathered through the programme will directly influence future MHRA policy and guidance.
The initiative follows the success of previous AI Airlock phases and benefits from a new three-year government funding commitment.
Applications are now open to eligible AI medical device developers, with successful participants due to be selected in November 2026.
As part of the government’s response, the MHRA has also committed to publishing draft guidance by December 2026 on managing changes to AI-enabled medical devices as they evolve over time.
The guidance will help establish a regulatory framework capable of maintaining patient safety while supporting innovation and timely access to new technologies.
Additionally, the MHRA plans to consult during 2027 on new approaches to the qualification and classification of AI-enabled medical devices, addressing the first recommendation made by the Commission.
The government has also pledged to explore new staged authorisation pathways that could allow promising AI tools to be introduced into NHS settings earlier under controlled conditions.
Under such an approach, technologies could be deployed while additional real-world evidence is gathered, helping innovators bring potentially beneficial tools to patients faster while maintaining regulatory safeguards.
A comprehensive implementation roadmap covering all 44 recommendations is expected to be published by Spring 2027, with regular progress reports to follow.
Beyond regulation, the government’s response places a strong emphasis on patient engagement, transparency and fairness.
Plans include increasing patient involvement in decision-making, improving access to redress where standards of care fall short, and ensuring the benefits of AI are distributed equitably across all communities, including underserved populations.
The announcement also signals a broader commitment to informing patients when AI technologies are being used as part of their care.
Lawrence Tallon, the MHRA’s Chief Executive, said:
“The independent National AI Commission, led by NHS doctors, has given us a clear and ambitious blueprint for how we make the UK the best place to get AI products to patients safely, quickly and in a way that maintains public trust. I am pleased that today the Government is accepting its recommendations in full, whilst setting out a clear plan and oversight structure to deliver them.
“The MHRA’s AI Airlock is already opening its doors to more innovators who want to help us understand how these technologies can be implemented and monitored safely throughout their working life. This is about making sure patients can benefit from safe, trusted AI more quickly, while never losing sight of the safeguards that maintain public confidence.”
AI Minister Kanishka Narayan said:
“AI has huge potential to help doctors deliver better care and improve outcomes for patients.
“We’re working to make promising new tools available to people across the country sooner, so everyone has the chance to benefit.”
The establishment of a new Programme Board will oversee delivery across government, the MHRA, NHS organisations and devolved administrations. Work is already underway across nine priority areas identified in the government’s response, with the full implementation roadmap due in Spring 2027.
The move represents one of the UK’s most significant policy shifts in healthcare AI regulation to date, placing lifecycle monitoring, patient safety and public trust at the centre of future innovation.
Image credit: iStock
Leave a comment